Involving the pharmaceutical and biotech communities in medication development for substance abuse

Pharmacology and Therapeutics

Volumn 108, Issue 1 SPEC. ISS., 2005, Pages 109-118

  Gorodetzky, Charles W ^a   Grudzinskas, Charles ^a  

^a NONE

Author keywords

Government; Incentives; Industry; Leadership; Partnership; Standards

Indexed keywords

BIOTECHNOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY; DATA BASE; DECISION MAKING; DRUG ABUSE; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; INDUSTRY; LABORATORY; LEADERSHIP; LEARNING; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUBSTANCE ABUSE;

EID: 25444463566     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.06.012     Document Type: Review

References (12)

1. Biomarkers Definitions Working Group Bethesda Md biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
2. College on Problems of Drug Development (CPDD) Workshop: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions, Bethesda, MD, April 19-20, 2005.
3. J. DiMasi Risks in new drug development: approval success rates for investigational drugs Clin Pharmacol Ther 69 2001 297 307
4. FDA End-of-Phase-2A Meetings with Sponsors Regarding Exposure-Response of IND and NDA Products 2003, October Draft
5. FDA Guidance for Industry Fast Track Drug Development Programs-Designation, Development, and Application Review 2004, July
6. FDA Guidance for Industry Investigators, and Reviewers-Exploratory IND Studies 2005, April Draft
7. FDA Guidance for Industry Applications Covered by Section 505(b)(2) 1999, October Available at: www.fda.gov/cder/guidance/2853dft.pdf
8. Fulco, et al. (eds.). (1995). The development of medications for the treatment of opiate and cocaine addiction: issues for the government and private sector. Report by the Institute of Medicine of the National Academy of Sciences.
9. L.J. Lesko, and A.J. Atkinson Use of biomarkers and surrogate endpoints in drug development and regulatory decision-making: criteria, validation, strategies Ann Rev Pharmacol Toxicol 41 2001 347 366
10. Park Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development Clin Cancer Res 10 2004 3885 3896
11. L.B. Sheiner Learning versus confirming in clinical drug development Clin Pharmacol Ther 61 1997 275 291
12. The Pink Sheets. (2005, May). FDC Reports, page 23.